ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3001

Exome Sequencing for Identification of Potential Causal Variants for Diffuse Cutaneous Systemic Sclerosis

Angel CY Mak1, Paul LF Tang2, Clare Cleveland3,4, M Kari Connolly5, Tamiko Katsumoto3,4, Paul Wolters6, Pui-Yan Kwok2,5 and Lindsey A. Criswell7, 1Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, 2Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, 3Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, San Francisco, CA, 4Department of Medicine, University of California, San Francisco, San Francisco, CA, 5Department of Dermatology, University of California, San Francisco, San Francisco, CA, 6Pulmonary Division, Department of Medicine, University of California, San Francisco, San Francisco, CA, 7Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: genetics, interstitial lung disease and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Scleroderma is a genetically complex autoimmune disease with substantial phenotypic heterogeneity. Previous genome-wide association studies (GWAS) have identified a large number of gene regions associated with disease risk.  However, GWAS directly capture only common genetic variants that are presumably in linkage disequilibrium with causal variants, some of which may be rare variants more frequently found in the disease population.  Our goal was to identify potentially causal variants by comparing whole exome sequencing data between cases and controls.  We focused on patients with severe disease, and specifically those with diffuse cutaneous systemic sclerosis (dcSSc), to limit disease heterogeneity.

Methods:

We produced whole exome sequencing data from 32 dcSSc patients on the Illumina HiSeq2500 platform with the Nimblegen SeqCap EZ v3.0 exome enrichment protocol. Paired-end 2 X 100 bp sequencing reads were generated with a mean coverage of 51X on the 64Mb of targeted exome regions. Control data came from 17 healthy control subjects whose data were produced using comparable methods, and from the 1000 Genomes and the NHLBI-ESP6500 Projects. Exome sequencing reads were processed according to the GATK Best Practices for DNAseq variant analysis. Variants were annotated and filtered with ANNOVAR and Variant Tools. We applied a gene mutation burden test to identify genes that were enriched with deleterious variants in dcSSc patients compared to controls.

Results:

We identified 96 genes that were enriched with deleterious variants in the dcSSc patients. Among the 96 genes, 10 genes (NOTCH4, BANK1, BLK, GRB10, IRF8, KCNA5, NMNAT2 and TNFSF4) are in previously identified scleroderma susceptibility loci or pathways implicated in scleroderma pathogenesis. In addition, we identified novel genes and 3 new pathways associated with scleroderma, including pathways related to ABC-family proteins mediated transport, extracellular matrix organization and the CD320-dependent methylmalonic aciduria.

Conclusion:

Using exome sequencing and gene mutation burden analysis, we identified 96 genes that contain functionally deleterious variants that may contribute to the development of dcSSc.  This study demonstrates the potential value of whole exome sequencing for the identification of causal variants that contribute to scleroderma risk and/or severity. The candidate genes we discovered are potential targets for in-depth functional study or therapeutics development.


Disclosure: A. C. Mak, None; P. L. Tang, None; C. Cleveland, None; M. K. Connolly, None; T. Katsumoto, None; P. Wolters, None; P. Y. Kwok, None; L. A. Criswell, None.

To cite this abstract in AMA style:

Mak AC, Tang PL, Cleveland C, Connolly MK, Katsumoto T, Wolters P, Kwok PY, Criswell LA. Exome Sequencing for Identification of Potential Causal Variants for Diffuse Cutaneous Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/exome-sequencing-for-identification-of-potential-causal-variants-for-diffuse-cutaneous-systemic-sclerosis-2/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/exome-sequencing-for-identification-of-potential-causal-variants-for-diffuse-cutaneous-systemic-sclerosis-2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology